| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | COVID-19 Triaged Papers | |||||||||||||||||||||||||
2 | Version 1 release date: May 26th, 2020 | |||||||||||||||||||||||||
3 | Contact: biogridadmin@gmail.com | |||||||||||||||||||||||||
4 | This file contains pre-published and published papers that were manually triaged by BioGRID for their relevance to the Coronavirus Disease 2019 (COVID-19) and its causative virus, SARS-CoV-2. It also contains papers relevant to two other related coronaviruses causing Severe Acute Respiratory Syndrom (SARS) and Middle Eastern Respiratory Syndrome (MERS), which emerged in 2002 and 2012, respectively. Several categories were flagged for each paper although BioGRID's main focus is on protein-protein and chemical interactions. This collection of triaged papers contains mostly full text papers that are freely available, which might be useful for other resources and as a gold standard set for text mining purposes. | |||||||||||||||||||||||||
5 | The column headers in the associated spreadsheets are the following: | |||||||||||||||||||||||||
6 | ||||||||||||||||||||||||||
7 | PRE-PUBLISHED PAPERS | |||||||||||||||||||||||||
8 | DOI | Article Digital Object Identifier (DOI) | ||||||||||||||||||||||||
9 | AUTHOR SHORT | First author and date | ||||||||||||||||||||||||
10 | TITLE | Title of article. The title might have been modified by the authors in different pre-published versions. | ||||||||||||||||||||||||
11 | ABSTRACT | Abstract of article. The abstract might have been modified by the authors in different pre-published versions. | ||||||||||||||||||||||||
12 | AUTHORS | Full author list (pipe delimited) | ||||||||||||||||||||||||
13 | DATE | Approximate date of online version of mansucript | ||||||||||||||||||||||||
14 | SOURCE | BioRxiv (www.biorxiv.org/) or MedRxiv (www.medrxiv.org/) | ||||||||||||||||||||||||
15 | LINK | Hyperlink to manuscript in BioRxiv or MedRxiv | ||||||||||||||||||||||||
16 | TEXT ANALYZER SCORE | Document score assigned using BioGRID's in-house Text Analyzer program. The higher the number of interaction-related keywords, the higher the document score. | ||||||||||||||||||||||||
17 | MATCHING KEYWORDS | Relevant interaction-related keywords detected in the title or abstract by BioGRID's Text Analyzer program. | ||||||||||||||||||||||||
18 | COVID-19 RELEVANT | Y/N (yes or no). Paper refers to the Coronavirus Disease 2019 and/or the underlying coronavirus, SARS-CoV-2. | ||||||||||||||||||||||||
19 | VIRAL PROTEIN INTERACTIONS | Y/N (yes or no). Paper includes either viral protein interactions or viral-host protein interactions, or both. This also includes computationally modelled and predicted interactions which will be accompanied by a "Y" in the computational only column. | ||||||||||||||||||||||||
20 | VIRAL CHEMICAL INTERACTIONS | Y/N (yes or no). Paper includes chemical-protein interactions that are relevant to the virus under study. This also includes computationally modelled and predicted interactions which will be accompanied by a "Y" in the computational only column. | ||||||||||||||||||||||||
21 | VIRUS | SARS-CoV-2, SARS-CoV, MERS, OTHER | ||||||||||||||||||||||||
22 | CLINICAL | Y/N (yes or no). A paper that includes patient studies or meta-analyses of clinical studies in the literature. Some papers can have both a clinical and research focus. | ||||||||||||||||||||||||
23 | RESEARCH | Y/N (yes or no). Paper has a research focus that is not specifically clinical in nature. Some papers can have both a clinical and research focus. This can include papers of case number forecasts, transmission rates, behavioral effects with a statistical basis. | ||||||||||||||||||||||||
24 | DRUGS OR ANTIBODIES | Y/N (yes or no). Paper includes studies focused on drugs or small molecules, and/or antibodies in relation to viral infections. | ||||||||||||||||||||||||
25 | OPEN ACCESS | Y/N (yes or no). Full text is freely available without any subscription. | ||||||||||||||||||||||||
26 | COMPUTATIONAL ONLY | Y/N (yes or no). Paper includes only computational analyses without any experimental results, or protein or viral interactions that are supported only by computational analysis even if other experimental data is presented in the paper. | ||||||||||||||||||||||||
27 | NOTES | Free text notes added by BioGRID. | ||||||||||||||||||||||||
28 | ||||||||||||||||||||||||||
29 | ||||||||||||||||||||||||||
30 | PUBLISHED PAPERS | |||||||||||||||||||||||||
31 | PMID | Pubmed ID for the paper | ||||||||||||||||||||||||
32 | SOURCE | Method for identification of the PMID as relevant for SARS-CoV, SARS-CoV-2 or MERS interaction curation | ||||||||||||||||||||||||
33 | SCORE | Ranked score of likelihood of protein-protein interactions in the title/abstract as determined by Pie The Search (PMID: 22199390). | ||||||||||||||||||||||||
34 | COVID-19 RELEVANT | Y/N (yes or no). Paper refers to the Coronavirus Disease 2019 and/or the underlying coronavirus, SARS-CoV-2. | ||||||||||||||||||||||||
35 | VIRAL PROTEIN INTERACTIONS | Y/N (yes or no). Paper includes either viral protein interactions or viral-host protein interactions, or both. This also includes computationally modelled and predicted interactions which will be accompanied by a "Y" in the computational only column. | ||||||||||||||||||||||||
36 | VIRAL CHEMICAL INTERACTIONS | Y/N (yes or no). Paper includes chemical-protein interactions that are relevant to the virus under study. This also includes computationally modelled and predicted interactions which will be accompanied by a "Y" in the computational only column. | ||||||||||||||||||||||||
37 | VIRUS | SARS-CoV-2, SARS-CoV, MERS, OTHER | ||||||||||||||||||||||||
38 | CLINICAL | Y/N (yes or no). A paper that includes patient studies or meta-analyses of clinical studies in the literature. Some papers can have both a clinical and research focus. | ||||||||||||||||||||||||
39 | RESEARCH | Y/N (yes or no). Paper has a research focus that is not specifically clinical in nature. Some papers can have both a clinical and research focus. | ||||||||||||||||||||||||
40 | DRUGS OR ANTIBODIES | Y/N (yes or no). Paper includes studies focused on drugs or small molecules, and/or antibodies in relation to viral infections. | ||||||||||||||||||||||||
41 | OPEN ACCESS | Y/N (yes or no). Full text is freely available without any subscription. | ||||||||||||||||||||||||
42 | COMPUTATIONAL ONLY | Y/N (yes or no). Paper includes only computational analyses without any experimental results, or protein or viral interactions that are supported only by computational analysis even if other experimental data is presented in the paper. | ||||||||||||||||||||||||
43 | NOTES | Free text notes added by BioGRID. | ||||||||||||||||||||||||
44 | ||||||||||||||||||||||||||
45 | ||||||||||||||||||||||||||
46 | ||||||||||||||||||||||||||
47 | ||||||||||||||||||||||||||
48 | ||||||||||||||||||||||||||
49 | ||||||||||||||||||||||||||
50 | ||||||||||||||||||||||||||
51 | ||||||||||||||||||||||||||
52 | ||||||||||||||||||||||||||
53 | ||||||||||||||||||||||||||
54 | ||||||||||||||||||||||||||
55 | ||||||||||||||||||||||||||
56 | ||||||||||||||||||||||||||
57 | ||||||||||||||||||||||||||
58 | ||||||||||||||||||||||||||
59 | ||||||||||||||||||||||||||
60 | ||||||||||||||||||||||||||
61 | ||||||||||||||||||||||||||
62 | ||||||||||||||||||||||||||
63 | ||||||||||||||||||||||||||
64 | ||||||||||||||||||||||||||
65 | ||||||||||||||||||||||||||
66 | ||||||||||||||||||||||||||
67 | ||||||||||||||||||||||||||
68 | ||||||||||||||||||||||||||
69 | ||||||||||||||||||||||||||
70 | ||||||||||||||||||||||||||
71 | ||||||||||||||||||||||||||
72 | ||||||||||||||||||||||||||
73 | ||||||||||||||||||||||||||
74 | ||||||||||||||||||||||||||
75 | ||||||||||||||||||||||||||
76 | ||||||||||||||||||||||||||
77 | ||||||||||||||||||||||||||
78 | ||||||||||||||||||||||||||
79 | ||||||||||||||||||||||||||
80 | ||||||||||||||||||||||||||
81 | ||||||||||||||||||||||||||
82 | ||||||||||||||||||||||||||
83 | ||||||||||||||||||||||||||
84 | ||||||||||||||||||||||||||
85 | ||||||||||||||||||||||||||
86 | ||||||||||||||||||||||||||
87 | ||||||||||||||||||||||||||
88 | ||||||||||||||||||||||||||
89 | ||||||||||||||||||||||||||
90 | ||||||||||||||||||||||||||
91 | ||||||||||||||||||||||||||
92 | ||||||||||||||||||||||||||
93 | ||||||||||||||||||||||||||
94 | ||||||||||||||||||||||||||
95 | ||||||||||||||||||||||||||
96 | ||||||||||||||||||||||||||
97 | ||||||||||||||||||||||||||
98 | ||||||||||||||||||||||||||
99 | ||||||||||||||||||||||||||
100 |